Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph plus ) leukemias resistant or intolerant to imatinib

被引：1
|
作者：
Rosenberg, J. A.
Derreumaux, D.
Gore, L.
Kearns, P.
Baruchel, A.
Barrett, T.
Zwaan, M.
机构：
[1] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Braine Lalleud, Belgium
[3] Univ Colorado Denver, Aurora, CO USA
[4] Childrens Hosp, Aurora, CO USA
[5] Univ Birmingham, Birmingham, W Midlands, England
[6] Hop St Louis, Paris, France
[7] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS281
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP).
    Kantarjian, H. M.
    Gattermann, N.
    O'Brien, S. G.
    Bhalla, K.
    Hochhaus, A.
    Cervantes, F.
    Alland, L.
    Ottmann, O.
    Giles, F.
    Le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 345S - 345S
  • [32] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [33] Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.
    Cervantes, Francisco
    Lopez-Garrido, Pilar
    Montero, Maria-Isabel
    Jonte, Femin
    Martinez, Jesus
    Hernan-dez-Boluda, Juan-Carlos
    Calbacho, Maria
    Sureda, Anna
    Perez-Rus, Gloria
    Nieto, Jose
    Perez-Lopez, Cristina
    Roman, Jose
    Gonzalez, Marcos
    Pereira, Arturo
    Colomer, Dolors
    BLOOD, 2009, 114 (22) : 456 - 457
  • [34] Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: Update of a phase I study.
    Sawyers, CL
    Kantarjian, H
    Shah, N
    Cortes, J
    Paquette, R
    Donato, N
    Nicoll, J
    Bleickardt, E
    Chen, TT
    Talpaz, M
    BLOOD, 2005, 106 (11) : 16A - 16A
  • [35] Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study
    Kantarjian, H.
    Shah, N. P.
    Hochhaus, A.
    Cortes, J. E.
    Shah, S.
    Ayala, M.
    Moiraghi, B.
    Bradley-Garelik, M.
    Zhu, C.
    Baccarani, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [36] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
    Khoury, H. J.
    Kim, D.
    Zaritskey, A.
    Apperley, J.
    Besson, N.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Results of a prospective phase 2 study combining imatinib, mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
    Gardembas, M
    Rousselot, P
    Tulliez, M
    Vigier, M
    Buzyn, A
    Rigal-Huguet, F
    Legros, L
    Michallet, M
    Berthou, C
    Cheron, N
    Maloisel, F
    Mahon, FX
    Facon, T
    Berthaud, P
    Guilhot, J
    Guilhot, F
    BLOOD, 2003, 102 (13) : 4298 - 4305
  • [38] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [39] Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials
    Guilhot, F
    Gardembas, M
    Rousselot, P
    Tulliez, M
    Vigier, M
    Buzyn, A
    Rigal-Huguet, F
    Legros, L
    Michallet, M
    Berthou, C
    Najman, A
    Maloisel, F
    Mahon, FX
    Facon, T
    Berthaud, P
    Guilhot, J
    SEMINARS IN HEMATOLOGY, 2003, 40 (02) : 92 - 97
  • [40] Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph plus ) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): Updated safety analysis
    Nicolini, F. E.
    Alimena, G.
    Al-Ali, H.
    Zaritskey, A. Y.
    Shen, Z.
    Jootar, S.
    Smith, G.
    Hsu, Y.
    Veronese, M. L.
    Rizzieri, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345